

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

نَرْفَعُ دَرَجَاتٍ مِّنْ نَّشَأٍ وَفَوْقَ كُلِّ ذِي عِلْمٍ عَلِيمٌ

صَدَقَ اللَّهُ الْعَظِيمُ

سورة يوسف (76)



Faculty of Science
Biochemistry Department



Biological Evaluation of Some Medicinal Plant Extracts Against Neuroinflammation Characterizing Alzheimer's Disease In Experimental Rat Model

Thesis Submitted by
Soheir El Sayed El Sayed Kotob

(B.Sc. 2003, M.Sc. 2008 in Biochemistry)

*In Fulfillment for the Degree of Doctor of Philosophy
(PhD) of Science in Biochemistry*

Supervisors

Prof/ Ahmed Mohammed Salem

Professor of Biochemistry

Biochemistry Department

Faculty of Science

Ain Shams University

Prof/ Gilane Mohamed Sabry

Professor of Biochemistry

Biochemistry Department

Faculty of Science

Ain Shams University

Prof/ Hanaa Hamdy Ahmed

Head of Hormones Dept.

Hormones Department

Medical Research Division

National Research Centre

Prof/ Ahmed Abdel Fatah Hussein

Prof. of Chemistry of Medicinal Plants

Chemistry of Medicinal Plants Dept.

Pharmaceutical and Drug Industries

Research Division

National Research Centre

Ain Shams University

Faculty of Science

Department of Biochemistry

(2014)

Acknowledgement

I would like to express my deepest gratitude to Prof. Ahmed Mohammed Salem, Professor of Biochemistry, Faculty of Science, Ain Shams University, for supervising the present work and his guidance, encouragement and continuous support throughout the course of this study and for reading and criticizing the manuscript. His valuable guidance and ultimate support are greatly appreciated.

Special thanks to Prof. Gilane Mohamed Sabry, Professor of Biochemistry, Faculty of Science, Ain Shams University, for her help, encouragement and direct sincere guidance throughout the present investigation and for her help during the preparation of the current study.

I am heartily thankful to Prof. Hanaa Hamdy Ahmed, Professor of Hormones, Hormones Department, Medical Research Division, National Research Centre, whose encouragement, guidance and support from the initial to the final level enabled me to develop this work. I cannot adequately express in words my appreciation and thanks to her for suggesting the problem, planning, reading and criticizing the manuscript, valuable supervision, constructive criticism, helpful discussion, time and great effort spent throughout the course of the current study.

My deepest thanks are to prof. Ahmed Abdel Fatah Hussein, Professor of Chemistry of Medicinal Plants, Chemistry of Medicinal Plants Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, for his guidance and cooperation in providing the studied medicinal plant extracts and carrying out the phytochemical studies in the current study.

A lot of thanks to Prof. Emad Fawzy Eskander, Professor of

Acknowledgment

Chemistry, Hormones Department, Medical Research Division, National Research Centre, for his assistance, sincere advise and encouragement throughout the time of the current study.

I am especially indebted to Prof. Adel Bakeer Kholoussy, Professor of pathology Faculty of Veterinary Medicine, Cairo University for his kind cooperation in conducting histopathological investigations in the current study.

Finally, I would like to express my deepest gratitude to the project team entitled "Development of Natural Drugs for Treatment of Neurodegenerative Diseases" which was funded from Academy of Scientific Research and Technology for funding and support the present work.

Soheir EL sayed EL sayed Kotob

Abstract

The current study was designed to explore the potent role of four medicinal plants namely *Salvia triloba*, *Piper nigrum*, *Ruta graveolens* and *Pegenum harmala* in management of neuroinflammatory insults characterizing Alzheimer's disease (AD) in experimental rat model. This aim was achieved by performing acute and chronic toxicological study for the selected medicinal plant extracts. The preclinical toxicological study for the selected medicinal plant extracts (Part I) was conducted from one hundred and sixty eight adult *Sprague Dawley* rats (eighty four male and eighty four female). On the other hand, the pharmacological study (Part II) was conducted from one hundred and ten adult male *Sprague Dawley* rats were classified into seven main groups: (1), control group; (2), AD-induced group in which the rats were orally administered with aluminum chloride (AlCl_3) (17 mg/kg b. wt) daily for one month (3), AD-induced group treated orally with Rivastigmine, the conventional therapy for AD (0.3 mg/kg b. wt) daily for three months; (4), AD-induced group which was further divided into two subgroups, the first subgroup was treated orally with *S. triloba* methanolic extract (750 mg/kg b. wt) and the second subgroup was treated orally with *S. triloba* (375 mg/kg b. wt) daily for three months; (5), AD-induced group which was further divided into two subgroups the first subgroup was treated orally with *P. nigrum* methanolic extract (187.5 mg/kg b. wt) and the second subgroup was treated orally with *P. nigrum* (93.75 mg/kg b. wt) daily for three months; (6), AD-induced group which was further divided into two subgroups, the first subgroup was treated orally with *R. graveolens* methanolic extract (750 mg/kg b. wt.) and the second subgroup was treated orally with *R.*

graveolens (375 mg/kg b. wt.) daily for three months and (7), AD-induced group which was divided into two subgroups the first subgroup was treated orally with *P. harmala* methanolic extract (375 mg/kg b. wt.) and the second subgroup was treated orally with *P. harmala* (187.5 mg/kg b. wt.) for daily for three months. Brain acetylcholine (ACh), brain and serum acetylcholinesterase (AChE) activities, C-reactive protein (CRP), total nuclear factor Kappa B₆₅ (NF-kB₆₅), monocyte chemoattractant protein-1 (MCP-1), cyclooxygenase-2 (COX-2), leukotriene B₄ (LTB₄) and B-cell lymphoma 2 (Bcl-2) levels were estimated. Histological investigation of brain sections of all studied groups were also carried out. The present results revealed that administration of AlCl₃ resulted in significant elevation in brain and serum AChE, CRP, NF kappa B, MCP-1, COX-2 and LTB₄ levels accompanied with significant depletion in brain Ach as well as brain and serum Bcl2 levels. Histological investigation of the brain of rats administered AlCl₃ showed the appearance of β -amyloid (A β) plaques characterizing AD. However, treatment of rats with the selected extracts produced marked improvement in the measured biochemical parameters as well as in the histological feature of the brain. The present study suggested that the studied medicinal plant extracts have a different degree of potentiality in alleviating AD. This promising effect was achieved through their powerful anti-cholinesterase activity, anti-inflammatory property and anti-apoptotic capacity. The current study represented good therapeutic approach for intervention against progressive neurological damage associated with AD.

Keywords: Alzheimer's disease, *Salvia triloba*, *Piper nigrum*, *Ruta graveolens*, *Pegenum harmala*, Inflammation, Apoptosis, Rat.

List of Content

Title	Page no.
1. INTRODUCTION	1-4
2. AIM OF THE WORK	5
3. REVOEW OF THE LITERATURE	6
3.1. Alzheimer's disease	6
3.1.1. Definition	6
3.1.2. History	6
3.1.3. Epidemiology	7
3.1.4. Clinical features	10
3.1.5. Neuropathological phenotype of AD	15
3.1.6. Amyloid homeostasis, A β clearance from the brain	16
3.1.7. A β generation, aggregation and deposition	18
3.1.8. Neurofibrillary tangles (NFTs)	24
3.1.9. Diagnosis	28
3.1.10. Risk factors for AD & Etiology	30
3.2. ALUMINIUM	39
3.2.1. Sources of Al	39
3.2.2. Aluminum and AD	42
3.3. AD and Oxidative stress	53
3.4. AD and inflammation	54
3.4.1. C-reactive protein (CRP)	58
3.4.2. Nuclear factor kappa B (NF- κ B)	59
3.4.3. Monocyte chemoattractant protein-1 (MCP-1)	62
3.4.4. Eicosanoids Cyclooxygenase (COX) and Lipoxygenase (LOX)	66
3.5. Apoptosis and AD	74
3.5.1. B-cell lymphoma-2 (Bcl-2)	75

3.6. Treatment Strategies	78
3.6.1. Current therapy for AD	78
3.6.2. Anti-inflammatory Agents	81
3.6.3. Nonsteroidal anti-inflammatory drugs (NSAIDs)	82
3.7. Medicinal plant therapy	83
3.7.1. <i>Salvia triloba</i>	84
3.7.1.1. Morphological description	84
3.7.1.2. Chemical constituents	85
3.7.1.3. Biological activities	87
3.7.2. <i>Piper nigrum</i>	91
3.7.2.1. Morphological description	91
3.7.2.2. Chemical constituents of <i>piper</i> species	92
3.7.2.3. Biological activities	93
3.7.3. <i>Ruta graveolens</i>	95
3.7.3.1. Morphological description	95
3.7.3.2. Chemical constituents	96
3.7.3.3. Biological activity	97
3.7.4. <i>Pegenum harmala</i>	100
3.7.4.1. Chemical constituents	100
3.7.4.2. Biological activities	102
4. MATERIALS AND METHODS	106
4.1. PART I: PRECLINICAL TOXICOLOGICAL STUDIES FOR THE SELECTED NATURAL PRODUCTS	106
4.1.1. Materials	106
4.1.1.1. Plants	106
4.1.1.2. Experimental animals	106
4.1.2. Methods	107
4.1.2.1. Plant extraction	107
4.1.2.2. Alcoholic extraction of the selected plants	107

4.1.2.3. Study design	107
4.1.2.3.1. Sage (<i>Salvia triloba</i> L.)	108
a- Protocol for an Acute Toxicity Study	108
b- Protocol for a Chronic Toxicity Study	108
4.1.2.3.2. Black pepper (<i>Piper nigrum</i>)	108
a- Protocol for an Acute Toxicity Study	108
b- Protocol for a Chronic Toxicity Study	109
4.1.2.3.3. <i>Ruta graveolens</i> L.	109
a- Protocol for an Acute Toxicity Study	109
b- Protocol for a Chronic Toxicity Study	109
4.1.2.3.4. Peganum (<i>Pegenum harmala</i>)	109
a- Protocol for an Acute Toxicity Study	109
b- Protocol for a Chronic Toxicity Study	110
4.1.2.4. Hematological methods	110
4.1.2.4.1. Quantitative measurement of blood hemoglobin concentration	110
4.1.2.4.2. Quantitative estimation of White blood cells Count	112
4.1.2.5. Biochemical analyses	113
4.1.2.5.1. Quantitative determination of serum aspartate aminotransferase (AST) activity	113
4.1.2.5.2. Quantitative determination of Serum Alanine Aminotransferase (ALT) activity	114
4.1.2.5.3. Quantitative determination of serum alkaline phosphatase (ALP) activity	116
4.1.2.5.4. Quantitative estimation of serum urea level	117
4.1.2.5.5. Quantitative estimation of serum creatinine level	119
4.1.2.6. Histopathological examinations	120
4.2. PART II: BIOCHEMICAL STUDY	121
4.2.1. Materials	121

A) Chemical and drug	121
B) Plants:	121
C) Experimental Design:	121
4.2.2. Methods	124
4.2.2.1. Plant extraction	124
4.2.2.2. Alcoholic extraction of the selected plants	124
4.2.2.3. Biochemical Analyses	124
4.2.2.3.1. Quantitative estimation of brain acetylcholine (ACh) level	124
4.2.2.3.2. Estimation of brain and serum acetylcholinesterase (AChE) activity	127
4.2.2.3.3. Quantitative estimation of brain and serum High sensitivity C-reactive protein (hsCRP)	128
4.2.2.3.4. Estimation of serum and brain Total NF- κ Bp65	131
4.2.2.3.5. Estimation of serum and brain monocyte chemoattractant protein-1 (MCP-1) levels	137
4.2.2.3.6. Estimation of serum and brain COX-2 level	142
4.2.2.3.7. Estimation of serum and brain LTB ₄ level	146
4.2.2.3.8. Estimation of B-cell lymphoma 2 (Bcl-2)	152
4.2.2.3.9. Determination of brain total protein	155
4.2.2.4. Histological Examination	157
4.3. Statistical analyses	157
5. RESULTS	158
5.1. PART I: PRECLINICAL TOXICOLOGICAL STUDIES ON THE SELECTED NATURAL PRODUCTS	158
5.1.1. Acute Toxicity Study	158
A. <i>Salvia triloba</i> L.	158
B. <i>Piper nigrum</i>	158
C. <i>Ruta graveolens</i> L.	158
D. <i>Peganum harmala</i> :	159

5.1.1.2. Chronic Toxicity Study	159
A) Hematological and Biochemical Analyses Results	159
B) Liver and Kidney function screening	161
C) Histopathological results of rats liver in chronic toxicity of the selected medicinal plants extracts	165
5.2. PART II: BIOCHEMICAL STUDIES AND HISTOPATHOLOGICAL INVESTIGATIONS OF THE SELECTED MEDICINAL PLANTS	170
A) Biochemical Analyses	170
a) Effects of treatment with the selected medicinal plants total extracts on cholinergic markers on AD-induced rats	170
b) Effects of treatment with the selected medicinal plants total extract on brain and serum inflammatory markers level on AD-induced rats	173
c) Effect of treatment with Rivastigmine and the selected medicinal plants total methanolic extract on brain and serum Bcl-2 levels in AD-induced rats	180
B) Histological investigations	182
6. DISCUSSION	188
7. SUMMARY AND CONCLUSION	223
8. REFERENCES	227
9. ARABIC SUMMARY	334

List of Abbreviations

4-HAD	4-hydroxyalkenals
5-HPETE	5-hydroperoxy eicosatetraenoic acid
5-LOX	5-lipoxygenase
9-me-BC	9-methyl-b-carboline
AA	Arachidonic acid
ACE	Angiotensin converting enzyme
Acetyl-CoA	Acetyl coenzyme A
ACh	Acetylcholine
AChE	Acetylcholinesterase
AChIs	Acetylcholinesterase inhibitors
AD	Alzheimer's disease.
AGEs	Advanced glycation endproducts
AICD	APP intracellular domain
AIF	Apoptosis inducing factor
AlCl₃	Aluminium chloride
ALP	Alkaline phosphatase
ALT	Alanine Aminotransferase
ANOVA	One way analysis of variance
ApoE	Apolipoprotein E gene
ApoE ϵ4	ϵ 4 allele apolipoprotein E genotype
APP	Amyloid precursor protein
AST	Aspartate aminotransferase
Aβ	Amyloid β
BACE1	β -site APP-cleaving enzyme
BACE1	Beta-site amyloid precursor protein cleaving enzyme
<i>Bad</i>	B cell lymphoma 2 associated death promoter

<i>Bak</i>	B cell lymphoma 2 homologous antagonist killer
<i>Bax</i>	B cell lymphoma 2 associated x protein
BBB	Blood brain barrier
BChE	Butyrylcholinesterase
Bcl-2	B-cell lymphoma-2
Bcl-xl	B cell lymphoma 2 extra large
BCs	β -carboline
BDNF	Brain derived neurotrophic factor
BIF	Brain interstitial fluid
C/EBP β	<u>cytidine</u> -cytidine- <u>adenosine</u> -adenosine- <u>thymidine</u> Enhancer Binding Protein Beta
CAA	Congophilic amyloid angiopathy
CAT	Catalase
CCR2	CCL2 (MCP-1) receptors
CDC	Center for Disease Control
Cdk5	Cyclin dependant kinase 5
ChAT	Cholineacetyltransferase
ChAT	Choline acetyl transferase
CMH	Cyanomethemoglobin
CNS	Central Nervous System
COX-2	Cyclooxygenase-2
cPLA2	Cytosolic phospholipase A2
CREB	cAMP response element-binding
CRP	C-reactive protein
CSF	Cerebrospinal fluid
CT	Computerized tomography
CT	Cryptotanshinone
α-CTF	α C- terminal fragment

CTS	Cryptotanshinone
CYP4Fs	Cytochrome P450 4Fs
DLA	3,4-Dihydroxyphenyl lactic acid
DNPH	2, 4- Dinitrophenyl hydrazine
DT	15, 16-Dihydrotanshinone I
ECE1	Endothelin converting enzyme 1
EEG	Electroencephalogram
EOAD	Early onset Alzheimer's disease
EOFAD	Early onset familial Alzheimer's disease
EPA	Environmental Protection Agency
FAβ	Fibrillar Amyloid β
FLAP	5-Lipoxygenase activating-protein
G-6-PD	Glucose-6-phosphate dehydrogenase
GFAP	Glial fibrillary acidic protein
GR	Glutathione reductase
GSK3β	Glycogen synthase kinase 3 beta
H₂O₂	Hydrogen peroxide
hcCRP	High sensitivity C-reactive protein
HRT	Hormone replacement therapy
HUVECs	Human umbilical vein endothelial cells
ICAM-1	Intercellular adhesion molecule-1
IDE	Insulin degrading enzyme
IFN-γ	Interferon- γ
IGF-1	Insulin-like growth factor-1
IκB	Inhibitory kappa B
IL-1β	Interleukin-1 β
iNOS	Inducible nitric oxide synthase
JNK	<i>c-Jun</i> N-terminal kinase

LDH	Lactate dehydrogenase
LOAD	Late onset Alzheimer's disease
LPS	Lipopolysaccharide
LRP1	Low-density lipoprotein receptor-related protein 1
LSD	Least significant difference
LT	Leukotrienes
LTB₄	Leukotrienes B ₄
mAChR	Muscarinic acetylcholine receptors
MAO	Monoamine oxidase
MAP	Microtubule associated protein
MAPK	Mitogen activated protein kinases
MAPK	Mitogen-activated protein kinase
MCI	Mild cognitive impairment
MCI	Mild cognitive impairment
MCP-1	Monocyte chemotactic protein-1
MCP-1 (CCL2)	Monocyte chemoattractant protein-1
MDMs	Monocyte-derived microglia
MLB	Magnesium lithospermate B
MMP9	Matrix metalloprotease 9
MMSE	Mini-Mental Status Examination
MRI	Magnetic resonance imaging
nAChR	Nicotinic acetylcholine receptors
NEP	Neprilysin
NF-κB	Nuclear factor kappa B
NFTs	Neurofibrillary tangles
NGF	Nerve growth factor
NINCDS-ADRDA	National Institute of Neurologic and Communicative Disorders and Stroke- AD